Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) closed at $2.09 in the last session, down -6.28% from day before closing price of $2.23. In other words, the price has decreased by -$6.28 from its previous closing price. On the day, 63331.0 shares were traded. BCLI stock price reached its highest trading level at $2.25 during the session, while it also had its lowest trading level at $2.01.
Ratios:
We take a closer look at BCLI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.05 and its Current Ratio is at 0.05.
Maxim Group reiterated its Buy rating for the stock on December 19, 2016, while the target price for the stock was revised from $5 to $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 01 ’24 when Lebovits Chaim bought 1,836 shares for $3.43 per share. The transaction valued at 6,292 led to the insider holds 80,960 shares of the business.
Lebovits Chaim bought 22,000 shares of BCLI for $5,016 on Sep 30 ’24. The President & CEO now owns 1,186,865 shares after completing the transaction at $0.23 per share. On Jul 19 ’24, another insider, Dagher Ibrahim B., who serves as the Chief Medical Officer of the company, sold 63,000 shares for $0.35 each. As a result, the insider received 22,069 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCLI now has a Market Capitalization of 11920168 and an Enterprise Value of 3924887.
Stock Price History:
The Beta on a monthly basis for BCLI is 0.27, which has changed by -0.5645833 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, BCLI has reached a high of $11.89, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 20.57%, while the 200-Day Moving Average is calculated to be -55.57%.
Shares Statistics:
According to the various share statistics, BCLI traded on average about 113.21K shares per day over the past 3-months and 83010 shares per day over the past 10 days. A total of 5.31M shares are outstanding, with a floating share count of 4.50M. Insiders hold about 21.14% of the company’s shares, while institutions hold 12.84% stake in the company. Shares short for BCLI as of 1730332800 were 109802 with a Short Ratio of 1.35, compared to 1727654400 on 124587. Therefore, it implies a Short% of Shares Outstanding of 109802 and a Short% of Float of 2.19.
Earnings Estimates
The stock of Brainstorm Cell Therapeutics, Inc (BCLI) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$2.1 and -$2.1 for the fiscal current year, implying an average EPS of -$2.1. EPS for the following year is -$1.59, with 2.0 analysts recommending between -$1.52 and -$1.65.
